LED Medical Diagnostics VELscope Vx® System to Be Used for Complimentary Oral Cancer Screenings at Leading Dental Show
Free Screenings Expected to Be a Highlight of Chicago Dental Societys
BURNABY, British Columbia February 20, 2013 - LED Medical Diagnostics Inc. ("LED Medical", "the Company"), a developer of tissue visualization detection technologies for the medical industry, said today that complimentary screenings featuring its VELscope Vx® enhanced oral assessment device will be offered to attendees at this week's Midwinter Meeting of the Chicago Dental Society. The screenings will take place February 21-23 at Booth #4411, which is operated by Den-Mat Holdings, the exclusive distributor of the VELscope Vx® in the worldwide dental market.
Visitors to Den-Mat's booth will receive both a clinical oral exam (COE), which involve an unaided visual inspection of the oral cavity and palpation of the neck and face, and an adjunctive screening with the VELscope Vx®. The screenings will be provided by volunteer registered dental hygienists. Literature regarding the need for earlier detection of oral cancer will be provided by the Oral Cancer Foundation.
LED Medical's VELscope Vx® technology is the first approved by the FDA and Health Canada to help clinicians discover cancerous and pre-cancerous tissue that might not be apparent to the naked eye. The VELscope Vx® is the world's most popular adjunctive oral screening device.
"With all of our progress over the past several years, the majority of dental practices are still not using an adjunctive screening device," said Peter Whitehead, CEO and Founder of LED Medical Diagnostics and its LED Dental subsidiary. "This event will help dental professionals appreciate that the combination of a COE and a VELscope Vx® screening is not only a surprisingly convenient way to enhance oral care, but a great way to attract new patients."
This will be the Chicago Dental Society's 148th Midwinter Meeting. One of the largest dental meetings in the world, it will attract thousands of dentists, dental hygienists, dental assistants, educators and other dental industry professionals.
Den-Mat manufactures a broad range of cosmetic and restorative solutions as well as innovative small equipment devices, available in the U.S. and over 68 countries worldwide. LUMINEERS®, the contact-lens thin veneer system is the flagship of Den-Mat's Smile Solutions portfolio, along with Snap-On Smile™, the Ultimate Provisional. Den-Mat also offers globally recognized brands such as Splash!® super-hydrophillic impression material, Lumibrite® chairside and take-home tooth whitening, Geristore® multi-use resin ionomer, FLASHLite® Portable LED Curing Light, and the Sapphire® platform of Plasma Arc Curing and SOL™ soft tissue diode laser. Recently, Den-Mat became the exclusive distributor of the VELscope Vx®, the worlds leading adjunctive oral cancer screening device. In addition to award-winning products, Den-Mat also offers a wide array of continuing education programs, including Destination Education events. For more information, call +1-800-445-0345 or visit www.denmat.com.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry.
Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope Vx® Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope Vx® devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 13,000 VELscope Vx® systems sold globally and they have been used to perform more than 25 million exams. For more information, visit www.leddental.com.
For media or investor relations inquiries, please contact:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.